Effect of sodium-glucose cotransporter 2 inhibitor dapagliflozin on systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity.
Nicola Maurea(Cancer Institute (WIA)), Vincenzo Quagliariello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giuseppe Palma(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Irma Bisceglia(Azienda Ospedaliera San Camillo-Forlanini), Francesca Izzo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), I Giacobbe(University of Campania "Luigi Vanvitelli"), Andrea Paccone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alessandro Inno(Ospedale Sacro Cuore Don Calabria), Matteo Barbato(University of Milan), Martina Iovine(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesca Bruzzese(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Laura Canale(Ospedale Versilia), Vienna Giordano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Raffaele Arianna(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Antonio Luciano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 1
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282